🟢 Haemonetics is trading 4.7% up in after-hours trading after CSL's planned rollout to U.S. plasma centers and Mizuho's price target hike

Haemonetics is trading at $124.27, up 4.67% in after-hours trading. This follows CSL's October 8 update on a planned rollout of Haemonetics devices across all its U.S. plasma centers by the end of 2027. Mizuho also maintained an Outperform rating and raised its price target for HAE from $95 to $140 on October 9, 2026.